S&P 500   3,263.05 (+0.51%)
DOW   26,877.81 (+0.23%)
QQQ   268.73 (+1.26%)
AAPL   110.35 (+1.97%)
MSFT   206.59 (+1.67%)
FB   251.36 (+0.73%)
GOOGL   1,427.74 (+0.34%)
AMZN   3,050.00 (+1.00%)
TSLA   405.62 (+4.60%)
NVDA   506.56 (+2.56%)
BABA   267.33 (-0.89%)
CGC   13.97 (-2.10%)
GE   6.04 (-0.33%)
MU   48.30 (-2.37%)
AMD   76.68 (+1.13%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.01 (-3.65%)
GILD   62.05 (-0.32%)
NFLX   477.75 (+0.99%)
DIS   122.44 (-0.04%)
BAC   23.28 (-0.26%)
BA   150.90 (+3.32%)
S&P 500   3,263.05 (+0.51%)
DOW   26,877.81 (+0.23%)
QQQ   268.73 (+1.26%)
AAPL   110.35 (+1.97%)
MSFT   206.59 (+1.67%)
FB   251.36 (+0.73%)
GOOGL   1,427.74 (+0.34%)
AMZN   3,050.00 (+1.00%)
TSLA   405.62 (+4.60%)
NVDA   506.56 (+2.56%)
BABA   267.33 (-0.89%)
CGC   13.97 (-2.10%)
GE   6.04 (-0.33%)
MU   48.30 (-2.37%)
AMD   76.68 (+1.13%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.01 (-3.65%)
GILD   62.05 (-0.32%)
NFLX   477.75 (+0.99%)
DIS   122.44 (-0.04%)
BAC   23.28 (-0.26%)
BA   150.90 (+3.32%)
S&P 500   3,263.05 (+0.51%)
DOW   26,877.81 (+0.23%)
QQQ   268.73 (+1.26%)
AAPL   110.35 (+1.97%)
MSFT   206.59 (+1.67%)
FB   251.36 (+0.73%)
GOOGL   1,427.74 (+0.34%)
AMZN   3,050.00 (+1.00%)
TSLA   405.62 (+4.60%)
NVDA   506.56 (+2.56%)
BABA   267.33 (-0.89%)
CGC   13.97 (-2.10%)
GE   6.04 (-0.33%)
MU   48.30 (-2.37%)
AMD   76.68 (+1.13%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.01 (-3.65%)
GILD   62.05 (-0.32%)
NFLX   477.75 (+0.99%)
DIS   122.44 (-0.04%)
BAC   23.28 (-0.26%)
BA   150.90 (+3.32%)
S&P 500   3,263.05 (+0.51%)
DOW   26,877.81 (+0.23%)
QQQ   268.73 (+1.26%)
AAPL   110.35 (+1.97%)
MSFT   206.59 (+1.67%)
FB   251.36 (+0.73%)
GOOGL   1,427.74 (+0.34%)
AMZN   3,050.00 (+1.00%)
TSLA   405.62 (+4.60%)
NVDA   506.56 (+2.56%)
BABA   267.33 (-0.89%)
CGC   13.97 (-2.10%)
GE   6.04 (-0.33%)
MU   48.30 (-2.37%)
AMD   76.68 (+1.13%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.01 (-3.65%)
GILD   62.05 (-0.32%)
NFLX   477.75 (+0.99%)
DIS   122.44 (-0.04%)
BAC   23.28 (-0.26%)
BA   150.90 (+3.32%)
Log in
NASDAQ:INZY

ALX Oncology Stock Forecast, Price & News

$22.22
-0.03 (-0.13 %)
(As of 09/25/2020 12:07 PM ET)
Add
Compare
Today's Range
$21.60
Now: $22.22
$22.22
50-Day Range
$20.80
MA: $26.05
$30.20
52-Week Range
$16.10
Now: $22.22
$31.65
Volume93 shs
Average Volume122,086 shs
Market Capitalization$519.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INZY
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees24
Market Cap$519.17 million
Next Earnings Date12/3/2020 (Estimated)
OptionableNot Optionable
$22.22
-0.03 (-0.13 %)
(As of 09/25/2020 12:07 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INZY News and Ratings via Email

Sign-up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ALX Oncology (NASDAQ:INZY) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of ALX Oncology?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ALX Oncology
.

When is ALX Oncology's next earnings date?

ALX Oncology is scheduled to release its next quarterly earnings announcement on Thursday, December 3rd 2020.
View our earnings forecast for ALX Oncology
.

How were ALX Oncology's earnings last quarter?

ALX Oncology Limited (NASDAQ:INZY) posted its quarterly earnings data on Thursday, September, 3rd. The company reported ($7.57) EPS for the quarter, missing the Zacks' consensus estimate of ($1.41) by $6.16.
View ALX Oncology's earnings history
.

What price target have analysts set for INZY?

5 analysts have issued 12-month price objectives for ALX Oncology's stock. Their forecasts range from $33.00 to $40.00. On average, they anticipate ALX Oncology's stock price to reach $35.25 in the next year. This suggests a possible upside of 58.6% from the stock's current price.
View analysts' price targets for ALX Oncology
.

Who are some of ALX Oncology's key competitors?

What other stocks do shareholders of ALX Oncology own?

When did ALX Oncology IPO?

(INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is ALX Oncology's stock symbol?

ALX Oncology trades on the NASDAQ under the ticker symbol "INZY."

When did the company's quiet period expire?

ALX Oncology's quiet period expired on Wednesday, September 2nd. ALX Oncology had issued 7,000,000 shares in its public offering on July 24th. The total size of the offering was $112,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of ALX Oncology?

Shares of INZY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ALX Oncology's stock price today?

One share of INZY stock can currently be purchased for approximately $22.22.

How big of a company is ALX Oncology?

ALX Oncology has a market capitalization of $519.17 million. ALX Oncology employs 24 workers across the globe.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.